RBC Capital Markets raises price target for Guardant Health
The investment bank RBC Capital Markets has updated its assessment of the US-based company Guardant Health. The analysts continue to view the stock positively and have reaffirmed their buy recommendation for the security.
As part of the new analysis, the price target for the stock was also raised. The target price increased from the previous 185 US dollars to 200 US dollars. This adjustment reflects the analysts' confidence in the company's future development.
Guardant Health is a biotechnology company that specializes in the development of blood tests for the early detection of cancer. Such companies are regularly in the focus of international investors, as their technological advancements can have an impact on the global healthcare market.
For investors in Germany who invest in international technology stocks, such analyst ratings are an important indicator of market valuation. The decision by RBC Capital Markets shows that experts continue to see potential in the medical diagnostics industry.